Hr - lysine demethylase and nuclear receptor corepressor Gene

Also Known as hr; bldy; ALUNC; rh-bmh

Species: Mus musculus

Gene Type: protein coding
Gene ID: 15460

Summary

This gene encodes a protein that is involved in hair growth. This protein functions as a transcriptional corepressor of multiple nuclear receptors, including Thyroid Hormone Receptor, the retinoic acid receptor-related orphan receptors and the vitamin D receptors, and it interacts with histone deacetylases. The translation of this protein is modulated by a regulatory ORF that exists upstream of the primary ORF. Mutations in this upstream ORF, U2HR, cause Marie Unna hereditary hypotrichosis (MUHH), an autosomal dominant form of genetic hair loss in human. [provided by RefSeq, Oct 2014]

Hr Products (2)

mRNA Protein Name
NM_001379479.1 NP_001366408.1 lysine-specific demethylase hairless
NM_021877.3 NP_068677.2 lysine-specific demethylase hairless

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence References Source
enables protein binding IPI
IPI: Inferred from physical interaction
11641275 MGI
enables transcription corepressor activity IDA
IDA: Inferred from direct assay
11641275 MGI
Biological Process GO Annotation Evidence References Source
acts upstream of or within negative regulation of DNA-templated transcription IDA
IDA: Inferred from direct assay
11641275 MGI
Cellular Component GO Annotation Evidence References Source
located in nuclear body IDA
IDA: Inferred from direct assay
11641275 MGI
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

lysine-specific demethylase hairless

  • [histone H3]-dimethyl-L-lysine(9) demethylase hairless

  • hairless

  • protein hairless

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (14)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-50767 Palbociclib Inhibitor 99.94% Unkown
HY-50767C Palbociclib hydrochloride Inhibitor 99.96% Unkown
HY-50767A Palbociclib monohydrochloride Inhibitor 99.98% Unkown
HY-A0065 Palbociclib isethionate Inhibitor 99.98% Unkown
HY-A0088A Cefotaxime Inhibitor 98.74% Unkown
HY-114778 Fluzoparib Inhibitor 99.96% Unkown
HY-A0088 Cefotaxime sodium Inhibitor 99.12% Unkown
HY-B1824 Cefpirome sulfate Inhibitor 99.49% Unkown
HY-B1824R Cefpirome sulfate (Standard) Inhibitor 99.04% Unkown
HY-50767AR Palbociclib monohydrochloride (Standard) Inhibitor 99.95% Unkown
HY-50767B Palbociclib dihydrochloride Inhibitor / Unkown
HY-50767D Palbociclib orotate Inhibitor / Unkown
HY-B1448A Benidipine Inhibitor / Unkown
HY-B0699 Cefpirome / Unkown

Clinical Phase

Bioactive Molecules (10)
Cat. No. Product Name Effect
Purity Phase
HY-171689 Puxitatug samrotecan Inhibitor 98.51% Phase 3
HY-W052011 Ruzinurad Inhibitor 99.26% Phase 3
HY-170442 ECI830 Inhibitor 98.01% Phase 2
HY-101813 Laflunimus Inhibitor 99.70% Phase 2
HY-45661 Inixaciclib Inhibitor 99.93% Phase 2
HY-106380 Glenvastatin Inhibitor / Phase 2
HY-19224 Fonsartan Antagonist / Phase 2
HY-182468 OP-3136 Inhibitor 99.90% Phase 1
HY-115552 Simmiparib Inhibitor 99.01% Phase 1
HY-183118 CID-078 / Phase 1

Pre-clinical Phase

Bioactive Molecules (62)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-W187305 MASM7 99.85% Unkown
HY-116770 PFM01 Inhibitor 99.91% Unkown
HY-159646 BMS-986397 99.76% Unkown
HY-N0272 Eleutheroside E Inhibitor 99.60% Unkown
HY-148226 20-5,14-HEDGE 99.28% Unkown
HY-147831 HR-19011 99.64% Unkown
HY-148078 PFM03 Inhibitor 99.86% Unkown
HY-N0252 Catharanthine Inhibitor 99.46% Unkown
HY-161430 RTx-161 98.0% Unkown
HY-161431 RTx-152 99.71% Unkown
HY-162384 EPIC-0628 Inhibitor 98.66% Unkown
HY-126972A RI(dl)-2 TFA Inhibitor 98.8% Unkown
HY-P2717 Ac-YVAD-AMC Inhibitor 99.64% Unkown
HY-W654101 Cefotaxime-d3 Inhibitor 98.00% Unkown
HY-180573 ART5537 Inhibitor 99.84% Unkown
HY-P10895 HR97 TFA 99.00% Unkown
HY-181557 SY-589 98.50% Unkown
HY-171159 MC-Val-Cit-PAB-Sunitinib 98.25% Unkown
HY-175812 MU876 Inhibitor 97.00% Unkown
HY-N0252A Catharanthine Tartrate Inhibitor 98.88% Unkown
HY-N0252B Catharanthine Sulfate Inhibitor / Unkown
HY-P3492 SARS-CoV-2-IN-34 Inhibitor / Unkown
HY-105879 Tepirindole / Unkown
HY-105907 Perafensine Inducer / Unkown
HY-106076 REV 2871 Inhibitor / Unkown
HY-115447 Clobenpropit Antagonist / Unkown
HY-117715 CK-3197 Inhibitor / Unkown
HY-126972 RI(dl)-2 Inhibitor / Unkown
HY-129934S Latanoprost ethyl amide-d4 / Unkown
HY-144338 PARP1/BRD4-IN-1 Inhibitor / Unkown
HY-144773A Loxoprofenol-SRS tromethamine Inhibitor / Unkown
HY-146194 NHEJ inhibitor-1 Activator / Unkown
HY-149972 Antitumor agent-96 Inducer / Unkown
HY-158733 HR68 / Unkown
HY-159091 HIV-1 integrase inhibitor 12 Inhibitor / Unkown
HY-162376 T3SS-IN-4 Inhibitor / Unkown
HY-163090 HR488B / Unkown
HY-168923 HR-568 Inhibitor / Unkown
HY-175466 BER-IN-1 / Unkown
HY-175482 PARP1-IN-43 Inhibitor / Unkown
HY-179413 Polθ-IN-9 Inhibitor / Unkown
HY-181026 RP-4029 Inhibitor / Unkown
HY-181611 Polθ-IN-10 / Unkown
HY-181840 MU262 Inhibitor / Unkown
HY-183285 PI3Kα-IN-32 Inhibitor / Unkown
HY-183748 Polθ-IN-11 / Unkown
HY-184649 CDK2-IN-60 Inhibitor / Unkown
HY-P10804 PIH Inhibitor / Unkown
HY-P1807 Mast Cell Degranulating Peptide HR-2 / Unkown
HY-P5398 HR2-18 Inhibitor / Unkown
HY-P5497 C34 peptide Inhibitor / Unkown
HY-P5727 HR1 Inhibitor / Unkown
HY-RS06353 HR Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-124823 Monastroline Inhibitor / Unkown
HY-129934 Latanoprost ethyl amide / Unkown
HY-157322 SAV13 / Unkown
HY-170775 AChE-IN-83 Inhibitor / Unkown
HY-A0088S Cefotaxime-d3 sodium Inhibitor / Unkown
HY-RS16724 Hr Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS23160 Hr Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-W654305 Palbociclib-d4 Inhibitor / Unkown
HY-W744633 Cefdaloxime Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Hr NCBI NCBI:55806